TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38054019

Group type: EXPERIMENTAL
Intervention: Instrument-assisted soft tissue mobilization (IASTM)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proprioceptive neuromuscular stretching (PNF)
Number of subjects: 0
Study: 38054386

Group type: EXPERIMENTAL
Intervention: Spinal cord stimulation (SCS)
Number of subjects: 0
Study: 38054504

Group type: EXPERIMENTAL
Intervention: Chronic-phase ICH patients
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 22
Study: 38054535

Group type: EXPERIMENTAL
Intervention: Client-centred HIV prevention model delivered by community health workers (CHWs) with clinician support; included structured client choice of product (PrEP or PEP), service location, and HIV testing modality, personalized support plan, and 24/7 clinician access.
Number of subjects: 429

Group type: EXPERIMENTAL
Intervention: Client-centred HIV prevention model delivered by community health workers (CHWs) with clinician support.
Number of subjects: 429

Group type: COMPARATOR
Intervention: Control group referred to local health facilities for HIV prevention services delivered by Ministry of Health staff.
Number of subjects: 429
Study: 38054555

Group type: EXPERIMENTAL
Intervention: Upper hemi-sternotomy
Number of subjects: 1395
Study: 38054564

Group type: EXPERIMENTAL
Intervention: Brief, skills-based alcohol intervention with baseline and 3-month in-person counselling sessions and interim booster phone calls every 3 weeks.
Number of subjects: 401

Group type: EXPERIMENTAL
Intervention: Brief, skills-based alcohol intervention.
Number of subjects: 401
Study: 38054604

Group type: EXPERIMENTAL
Intervention: CARE's Tipping Point Program
Number of subjects: 0
Study: 38054696

Group type: EXPERIMENTAL
Intervention: JX11502MA 0.25 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JX11502MA 0.5 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JX11502MA 1 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JX11502MA 2 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JX11502MA 3 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JX11502MA 6 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: JX11502MA 8 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38054726

Group type: EXPERIMENTAL
Intervention: FL058 alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FL058 in combination with meropenem
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FL058/meropenem combination
Number of subjects: 0
Study: 38054932

Group type: EXPERIMENTAL
Intervention: Dynamic choice patient-centered intervention (travel pack, multimonth and offsite refills, facilitated transfer, hotline access)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Dynamic choice patient-centered intervention
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 201
Study: 38055007

Group type: EXPERIMENTAL
Intervention: PICU admission
Number of subjects: 296

Group type: COMPARATOR
Intervention: Non-PICU group
Number of subjects: 296
Study: 38055176

Group type: EXPERIMENTAL
Intervention: Dual-pathway inhibition (DPI) with rivaroxaban and low-dose aspirin
Number of subjects: 33
Study: 38055186

Group type: EXPERIMENTAL
Intervention: Oral treprostinil
Number of subjects: 690

Group type: EXPERIMENTAL
Intervention: Oral treprostinil after clinical worsening
Number of subjects: 690

Group type: COMPARATOR
Intervention: Placebo followed by oral treprostinil after clinical worsening
Number of subjects: 690
Study: 38055237

Group type: EXPERIMENTAL
Intervention: Telemonitoring strategy (4 daily SMS messages)
Number of subjects: 699

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 699

Group type: EXPERIMENTAL
Intervention: Telemonitoring strategy
Number of subjects: 699

Group type: COMPARATOR
Intervention: Telemonitoring strategy and Standard care
Number of subjects: 699
Study: 38055242

Group type: EXPERIMENTAL
Intervention: RGRN-305, 250-mg tablet, once daily for 16 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo, matching tablet, once daily for 16 weeks
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: RGRN-305
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: COMPARATOR
Intervention: RGRN-305 and Placebo
Number of subjects: 15
Study: 38055253

Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine (MIRV) 6 mg/kg every 3 weeks
Number of subjects: 453

Group type: COMPARATOR
Intervention: Chemotherapy (paclitaxel, pegylated liposomal doxorubicin, or topotecan)
Number of subjects: 453

Group type: EXPERIMENTAL
Intervention: Mirvetuximab soravtansine (MIRV)
Number of subjects: 453

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 453
Study: 38055280

Group type: EXPERIMENTAL
Intervention: HCW-collected throat specimens
Number of subjects: 2674

Group type: EXPERIMENTAL
Intervention: HCW-collected nasal specimens
Number of subjects: 2674

Group type: EXPERIMENTAL
Intervention: Self-collected nasal specimens
Number of subjects: 2674

Group type: EXPERIMENTAL
Intervention: Self-collected throat specimens
Number of subjects: 2674

Group type: EXPERIMENTAL
Intervention: Combining nasal and throat specimens (HCW-collected)
Number of subjects: 2674

Group type: EXPERIMENTAL
Intervention: Combining nasal and throat specimens (self-collected)
Number of subjects: 2674
Study: 38055283

Group type: EXPERIMENTAL
Intervention: Magnetic Seizure Therapy (MST)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Electroconvulsive Therapy (ECT)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: MST
Number of subjects: 73

Group type: COMPARATOR
Intervention: ECT
Number of subjects: 73
Study: 38055284

Group type: EXPERIMENTAL
Intervention: Laparoscopic Roux-en-Y gastric bypass
Number of subjects: 457

Group type: COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: SF-BARI Score
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: SF-BARI Score QOL
Number of subjects: 457
Study: 38055309

Group type: EXPERIMENTAL
Intervention: VR multiplayer recreation and socialization using Meta Quest 2 headset, 4 weeks duration, 2×1-hour sessions per week.
Number of subjects: 12
Study: 38055353

Group type: EXPERIMENTAL
Intervention: MR-guided stereotactic body radiation therapy (SBRT) with 40 Gy prescribed to 95% of the PTV in over five fractions
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Hybrid model combining dosimetric features with clinical parameters
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Interactive grouped greedy algorithm (IGA) for dosimetric feature selection
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Dosimetric features selected by IGA
Number of subjects: 69
Study: 38055641

Group type: EXPERIMENTAL
Intervention: High Healthy Eating Index (HEI ≥ 58.89)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Mid Healthy Eating Index (HEI ≥ 47.94 and < 58.89)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Low Healthy Eating Index (HEI < 47.94)
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Added sugar ≤ 10% of calories
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Higher percentage of calories from fat
Number of subjects: 119
Study: 38055647

Group type: EXPERIMENTAL
Intervention: Neonatal cholestasis
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Progression to liver transplant
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Coagulopathy and varices
Number of subjects: 165
Study: 38056100

Group type: EXPERIMENTAL
Intervention: Aerobic + Resistance Exercises (AE + RE)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control (C)
Number of subjects: 90
Study: 38056411

Group type: EXPERIMENTAL
Intervention: Mandala coloring
Number of subjects: 77

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 77
Study: 38056467

Group type: EXPERIMENTAL
Intervention: Double ABCX-based psychotherapy
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (CoG)
Number of subjects: 201
Study: 38056464

Group type: EXPERIMENTAL
Intervention: Bexmarilimab
Number of subjects: 138
Study: 38056546

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) with the Edwards SAPIEN 3/SAPIEN 3 Ultra transcatheter heart valve
Number of subjects: 900

Group type: COMPARATOR
Intervention: Clinical surveillance
Number of subjects: 900
Study: 38056770

Group type: EXPERIMENTAL
Intervention: Decision support tool for managing oral anticoagulation (visualized in intervention centers)
Number of subjects: 44556
Study: 38056772

Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon (SCB) in ACS
Number of subjects: 2083

Group type: EXPERIMENTAL
Intervention: Sirolimus-coated balloon (SCB) in CCS
Number of subjects: 2083
Study: 38056900

Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) combined with adenosine pathway inhibitor oleclumab and neo-adjuvant immuno-chemotherapy (paclitaxel, doxorubicin/cyclophosphamide, durvalumab)
Number of subjects: 6
Study: 38056935

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Sham EA
Number of subjects: 168
Study: 38056945

Group type: EXPERIMENTAL
Intervention: mHealth-supported stroke prevention programme (n=52)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Ordinary primary healthcare (PHC) services
Number of subjects: 104
Study: 38057072

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 192

Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 192
Study: 38057314

Group type: EXPERIMENTAL
Intervention: Nivolumab (N)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Nivolumab + nab-paclitaxel + carboplatin (N/C)
Number of subjects: 52
Study: 38057377

Group type: EXPERIMENTAL
Intervention: BIS group (10 mg/kg/h propofol infusion adjusted to keep the BIS value between 40 and 60)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Bolus group (0.5 mg/kg of propofol when necessary)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: BIS group
Number of subjects: 130

Group type: COMPARATOR
Intervention: Bolus group
Number of subjects: 130
Study: 38057574

Group type: EXPERIMENTAL
Intervention: Maternal singing
Number of subjects: 30
Study: 38057636

Group type: EXPERIMENTAL
Intervention: Cipaglucosidase alfa plus miglustat (20 mg/kg intravenous-infused cipa plus 260 mg oral mig biweekly)
Number of subjects: 29
Study: 38057656

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg (FIL200) + MTX
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Filgotinib 200 mg (FIL200) + csDMARDs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab + MTX
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adalimumab
Number of subjects: 0
Study: 38057662

Group type: EXPERIMENTAL
Intervention: IL-4 signalling axis intervention, specific details not provided
Number of subjects: 0
Study: 38057695

Group type: EXPERIMENTAL
Intervention: Epidural nalbuphine (2 ml, 10 mg)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Epidural dexmedetomidine (2 ml, 100 µg)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Epidural bupivacaine (10 ml 0.25% + 2 ml normal saline)
Number of subjects: 69
Study: 38057709

Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (VO2)
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Moderate to vigorous physical activity (MVPA)
Number of subjects: 72
Study: 38057772

Group type: EXPERIMENTAL
Intervention: LXI-15029, 110 mg BID (maximum tolerated dose)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: LXI-15029
Number of subjects: 24
Study: 38057820

Group type: EXPERIMENTAL
Intervention: COVID-19 vaccination
Number of subjects: 67
Study: 38057844

Group type: EXPERIMENTAL
Intervention: Vildagliptin (50 mg tablet) with iftar meal during Ramadan
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no vildagliptin)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Vildagliptin
Number of subjects: 50
Study: 38057875

Group type: EXPERIMENTAL
Intervention: 40 mg pantoprazole intravenously
Number of subjects: 4800

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4800
Study: 38057919

Group type: EXPERIMENTAL
Intervention: BCG vaccine
Number of subjects: 2398

Group type: EXPERIMENTAL
Intervention: HepB3 vaccine
Number of subjects: 2398
Study: 38057927

Group type: EXPERIMENTAL
Intervention: Multiple intervention modalities for S. aureus bloodstream infection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 38057930

Group type: EXPERIMENTAL
Intervention: Ankle and 1st metatarsophalangeal (MTP) joint mobilisations and home-based stretches
Number of subjects: 61
Study: 38058024

Group type: EXPERIMENTAL
Intervention: Y2TEC intervention (12 sessions, 20-30 minutes each, delivered via videoconferencing and text messaging)
Number of subjects: 0
Study: 38058356

Group type: EXPERIMENTAL
Intervention: miRNAs as a therapeutic intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: miRNAs as a diagnostic tool
Number of subjects: 0
Study: 38058551

Group type: EXPERIMENTAL
Intervention: Participants who experienced a fall; Pain was the most frequent outcome reported (53%).
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Participants who experienced a fall; 73.5% reported experiencing a fall in the previous year.
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Participants who experienced a fall; 66.7% of those falls required assistance from Emergency Medical Services (EMS).
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Participants who experienced a fall; Nearly 40% did not take proactive steps to prevent future falls.
Number of subjects: 951

Group type: EXPERIMENTAL
Intervention: Participants who experienced a fall; Walking aids were the most common preventive action taken (79.8%).
Number of subjects: 951
Study: 38058646

Group type: EXPERIMENTAL
Intervention: Exercise therapy program using elastic bands (16 sessions, 45 minutes each)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual lifestyle (control group)
Number of subjects: 35
Study: 38058795

Group type: EXPERIMENTAL
Intervention: Semaglutide 0.1, 0.2, or 0.4 mg
Number of subjects: 122

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study: 38059202

Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture (IA) at gallbladder meridian acupoint (GBA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture (IA) at non-acupoint (NA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy control group (no intervention)
Number of subjects: 60
Study: 38059206

Group type: EXPERIMENTAL
Intervention: Return to work (RTW) program
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 70
Study: 38059368

Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Number of subjects: 817

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 817
Study: 38059497

Group type: EXPERIMENTAL
Intervention: Arfolitixorin (120 mg/m2 given as two intravenous bolus doses of 60 mg/m2)
Number of subjects: 490

Group type: COMPARATOR
Intervention: Leucovorin (400 mg/m2 given as a single intravenous infusion)
Number of subjects: 490

Group type: EXPERIMENTAL
Intervention: Arfolitixorin
Number of subjects: 490

Group type: COMPARATOR
Intervention: Leucovorin
Number of subjects: 490
Study: 38059611

Group type: EXPERIMENTAL
Intervention: Burr hole trepanation with burr hole covers
Number of subjects: 78

Group type: COMPARATOR
Intervention: Burr hole trepanation without burr hole covers (control)
Number of subjects: 78
Study: 38059635

Group type: EXPERIMENTAL
Intervention: Oral ceftibuten
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38059722

Group type: EXPERIMENTAL
Intervention: 2021 ERC/ESICM algorithm for neuroprognostication with GCS-M 1-3
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Broadening criteria to include patients with ongoing sedation
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Including all unconscious patients (GCS-M 1-5) regardless of sedation
Number of subjects: 794
Study: 38059837

Group type: EXPERIMENTAL
Intervention: Mild TBI
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Mild TBI (ages 28 to 40)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Mild TBI (ages 25 to 27 and 28 to 40)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Mild TBI (younger age group)
Number of subjects: 903

Group type: EXPERIMENTAL
Intervention: Mild TBI (older age group)
Number of subjects: 903
Study: 38059896

Group type: EXPERIMENTAL
Intervention: Metoclopramide
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 38059899

Group type: EXPERIMENTAL
Intervention: Pregnancy after breast cancer
Number of subjects: 4732
Study: 38059932

Group type: EXPERIMENTAL
Intervention: Brief video-based positive mood intervention (fixed content)
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: Brief video-based positive mood intervention (participant choice)
Number of subjects: 654

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 654

Group type: EXPERIMENTAL
Intervention: All groups (including both interventions and usual care)
Number of subjects: 654
Study: 38059944

Group type: EXPERIMENTAL
Intervention: Supportive Therapy (ST)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Expressive Techniques (SET)
Number of subjects: 118
Study: 38059943

Group type: EXPERIMENTAL
Intervention: Parent-Child Interaction Therapy (PCIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care as usual (SAU)
Number of subjects: 0
Study: 38059946

Group type: EXPERIMENTAL
Intervention: 0.60 g/kg alcohol during late follicular phase (E2 elevated)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo during early follicular phase (E2 low)
Number of subjects: 50
Study: 38060016

Group type: EXPERIMENTAL
Intervention: Informational video prior to amniocentesis
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard care (control group)
Number of subjects: 100
Study: 38060020

Group type: EXPERIMENTAL
Intervention: Emotion regulation training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 38060066

Group type: EXPERIMENTAL
Intervention: RT-FUS (2 Gy)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: RT-FUS
Number of subjects: 6

Group type: COMPARATOR
Intervention: RT
Number of subjects: 6
Study: 38060077

Group type: EXPERIMENTAL
Intervention: Compression therapy
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Cryotherapy
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 38060092

Group type: EXPERIMENTAL
Intervention: Fast-eluting implant (n = 51)
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Slow-eluting implant (n = 54)
Number of subjects: 154

Group type: COMPARATOR
Intervention: Timolol (n = 49)
Number of subjects: 154
Study: 38060195

Group type: EXPERIMENTAL
Intervention: Omission of radiotherapy with endocrine therapy for 5 years
Number of subjects: 200
Study: 38060199

Group type: EXPERIMENTAL
Intervention: Triplet therapy (atezolizumab 840 mg, ipatasertib 400 mg/day, paclitaxel 80 mg/m2 or nab-paclitaxel 100 mg/m2)
Number of subjects: 317

Group type: EXPERIMENTAL
Intervention: Triplet therapy
Number of subjects: 317
Study: 38060250

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Tai Chi (TC)
Number of subjects: 226

Group type: COMPARATOR
Intervention: Control Group
Number of subjects: 226
Study: 38060285

Group type: EXPERIMENTAL
Intervention: Hombres Saludables PA intervention arm
Number of subjects: 38

Group type: COMPARATOR
Intervention: Nutrition and wellness attention contact control arm
Number of subjects: 38
Study: 38060340

Group type: EXPERIMENTAL
Intervention: IGV-001
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 38060453

Group type: EXPERIMENTAL
Intervention: 4 weeks of multimodal prehabilitation (supervised physical training, nutritional support, medical optimization)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard of care (control group)
Number of subjects: 40
Study: 38060545

Group type: EXPERIMENTAL
Intervention: Psychoeducational video prescriptions about BPD
Number of subjects: 100

Group type: COMPARATOR
Intervention: Psychoeducational video prescriptions about non-BPD mental health topics
Number of subjects: 100
Study: 38060549

Group type: EXPERIMENTAL
Intervention: CSMT
Number of subjects: 320

Group type: COMPARATOR
Intervention: Sham CSMT
Number of subjects: 320

Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo medicine
Number of subjects: 320
Study: 38060584

Group type: EXPERIMENTAL
Intervention: 'sit less, move more, sleep better' program for up to 1 hour/day, 5 days/week, for 6 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: usual inpatient and early supported stroke discharge care
Number of subjects: 50
Study: 38060611

Group type: EXPERIMENTAL
Intervention: Intensified screening strategy combining nurse-driven screening for asymptomatic/paucisymptomatic patients with routine practice
Number of subjects: 138352

Group type: COMPARATOR
Intervention: Routine practice (control) including screening for symptomatic or hospitalized patients
Number of subjects: 138352
Study: 38060997

Group type: EXPERIMENTAL
Intervention: Transcatheter edge-to-edge repair (TEER) with the MitraClip™ device plus guideline-directed medical therapy (GDMT)
Number of subjects: 567

Group type: COMPARATOR
Intervention: Guideline-directed medical therapy (GDMT) alone
Number of subjects: 567
Study: 38061041

Group type: EXPERIMENTAL
Intervention: Vaginal estrogen (perioperative, 5 weeks or more preoperatively and 12 months postoperatively)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 186
Study: 38061271

Group type: EXPERIMENTAL
Intervention: 100 mg/kg ARA and 50 mg/kg DHA (ARA:DHA group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Medium chain triglycerides (control)
Number of subjects: 120
Study: 38061288

Group type: EXPERIMENTAL
Intervention: Palbociclib
Number of subjects: 287
Study: 38061339

Group type: EXPERIMENTAL
Intervention: Xerna™ TME Panel biomarker-positive patients (IA subtype)
Number of subjects: 22
Study: 38061346

Group type: EXPERIMENTAL
Intervention: VExUS-guided decongestion
Number of subjects: 140

Group type: COMPARATOR
Intervention: Usual clinical evaluation (Control)
Number of subjects: 140
Study: 38061367

Group type: EXPERIMENTAL
Intervention: VAX-24 (1·1 μg of each antigen, 2·2 μg of each antigen, or 2·2 μg of 17 antigens mixed with 4·4 μg of seven antigens)
Number of subjects: 416

Group type: EXPERIMENTAL
Intervention: VAX-24 (2·2 μg)
Number of subjects: 416

Group type: COMPARATOR
Intervention: PCV20
Number of subjects: 416